MH

Mark Haberlin

Australian Clinical Labs Limited | Non-Executive Director
Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate, and financial services. Mark is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Previously, Mark was an independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Holdings Limited, the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific. He is also member of the Risk Committee.

Companies and Roles

Company
Title
Tenure
Since
ACL
Australian Clinical Labs Limited
  • Non-Executive Director
3yrs, 2mthApr 2021
ABG
Abacus Group
  • Non-Executive Director
5yrs, 8mthNov 2018

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ABG
Abacus Group
30/06/23N/A42,292N/AN/A
ACL
Australian Clinical Labs Limited
30/06/23N/A47,500N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ACL
Australian Clinical Labs Limited
22/11/21
Buy
22,500$4.399$98,988On-market trade